At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 94 enrolled
Drug / intervention
VEGF Trapbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating VEGF Trap for Metastatic Renal Cell Carcinoma. Completed, enrolled 94 participants across 205 sites in 2 countries.
Detailed Summary
This randomized phase II trial studies how well ziv-aflibercept (VEGF Trap) works in treating patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) or is unable to be removed with surgery (unresectable). Ziv-aflibercept may stop the growth of kidney cancer by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
CountriesPeru, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2006
Enrollment StartDec 2007
Primary CompletionOct 2015
TodayJul 2026
First PostedJul 27, 2006
Enrollment StartDec 1, 2007
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 19.9 years ago
Interventions
VEGF Trapbiological
Given IV